Vertex stock surged 5.7% to 499.88. Shares are forming a flat base with a buy point at 510.63, according to MarketSurge. But the stock is flirting with a downtrend line between 499.09 and 500.25 ...

Vertex has built its earnings thanks to its CF program, and with a new CF drug approved a few months ago, the company may be ...

One key financial ratio used to measure how well a company converts its profit to free cash flow (FCF) is the accrual ratio. In plain english, this ratio subtracts FCF from net profit, and divides ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...

Vertex Pharmaceuticals on Monday reported disappointing ... Such standards have become a flash point in the nation’s culture wars and a source of conservative resistance to former president ...

This 11-point scale ranges from 0 (no pain ... Secondary and other endpoints were consistent with the study’s primary endpoint. Vertex also conducted post-hoc analyses to further evaluate ...

Vertex, CRISPR score landmark FDA approval for ... with 25 under its belt at the time. At that point in mid-April, five patients had had their cells collected across the U.S., Europe and the ...

With suzetrigine, developed by pharmaceutical company Vertex, they finally succeeded ... cut pain by about three points on the standard 10-point pain rating scale. Suzetrigine worked faster ...